HER2-POSITIVE ADVANCED BREAST CANCER
Clinical trials for HER2-POSITIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat breast cancer: advanced drug trial seeks to control disease
Disease control Recruiting nowThis study is testing whether a new drug called TQB2930, when given with chemotherapy, works better than the current standard treatment for people with advanced HER2-positive breast cancer that has worsened after at least two prior anti-HER2 treatments. It will involve 416 adults…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
First human trial launches for experimental cancer 'Breaker' drug
Disease control Recruiting nowThis is the first human study testing a new experimental drug called BBO-10203 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find safe doses and see how the body processes the drug, both alone and when combined with oth…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New scan could match patients to best drug after treatment fails
Disease control Recruiting nowThis study is for people with advanced HER2-positive breast cancer whose disease has worsened on a specific drug (T-DXd). It tests if a special imaging scan (HER2-PET/CT) can predict who might benefit from switching to another targeted drug (T-DM1). Patients get the scan and a bi…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC